Oncolytic Increases Autophagy in Multiple Myeloma
Overview
Authors
Affiliations
Objective: Multiple myeloma, which affects plasma cells, is the second most common hematological malignancy. Despite the development of new drugs and treatment protocols, patient survival has not reached the desired level. In this study, we investigated the effects of (MYXV), an oncolytic virus, on autophagy in myeloma cells.
Materials And Methods: We analyzed protein expressions of ATG-5, p62, Beclin-1, LC3B, and the apoptosis marker Bcl-2 as autophagy markers in human U-266 and mouse MOPC-315 myeloma cell lines subjected to different doses of MYXV. In addition, autophagic images of myeloma cells were investigated using transmission electron microscopy (TEM).
Results: In the first 24 h, which is the early stage of autophagy, ATG-5 and Beclin-1 expression levels were increased in the U-266 and MOPC-315 cell lines in the groups that had received MYXV at a multiplicity of infection of 15. At 48 h, a significant increase was detected in the expression of LC3B, which is a late indicator. Autophagosomes were observed in myeloma cells by TEM.
Conclusion: MYXV shows an antimyeloma effect by increasing autophagy in myeloma cells.
Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.
Raimondi V, Vescovini R, Dessena M, Donofrio G, Storti P, Giuliani N Front Immunol. 2024; 15:1483806.
PMID: 39539548 PMC: 11557349. DOI: 10.3389/fimmu.2024.1483806.